Utama › Kanser Paru-paru › Georgia › Atlanta
Kajian klinikal Kanser Paru-paru di Atlanta, GA
29 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Atlanta (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Northside Hospital, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Atlanta VA Medical Center, Decatur · 6 mi jauh
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Mengambil pesertaFasa 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Mengambil pesertaFasa 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
- dan 1 lagi
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Mengambil pesertaFasa 3
- Winship Cancer Institute of Emory University, Atlanta
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Mengambil pesertaFasa 3
- Piedmont Healthcare, Inc, Atlanta
- Winship Cancer Institute, Atlanta
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Mengambil pesertaFasa 3
- Piedmont Atlanta Hospital ( Site 4000), Atlanta
- Emory University School of Medicine-Phase I ( Site 0056), Atlanta
- Northside Hospital ( Site 0055), Atlanta
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Mengambil pesertaFasa 2/3
- Piedmont Healthcare, Atlanta
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Mengambil peserta
- Emory Clinic at Old Fourth Ward, Atlanta
- Emory Clinic at Midtown, Atlanta
- Emory at Peachtree Hills - Primary Care, Atlanta
- dan 19 lagi
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Mengambil pesertaFasa 1/2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Piedmont Cancer Institute, PC, Atlanta
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Emory University School of Medicine- Grady Campus, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Mengambil pesertaFasa 1
- Emory University, Atlanta
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Mengambil pesertaFasa 1/2
- Avenzo Therapeutics Recruiting Site, Atlanta
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Mengambil pesertaFasa 3
- Northside Hospital Atlanta, Atlanta
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Mengambil pesertaFasa 1
- Emory University - Winship Cancer Institute, Atlanta
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Grady Health System, Atlanta
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
- dan 3 lagi
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
- Xencor Investigative Site, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Mengambil pesertaFasa 1/2
- Winship Cancer Institute - Emory University, Atlanta
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Northside Hospital, Atlanta
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Mengambil pesertaFasa 1/2
- Piedmont Healthcare, Atlanta
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- dan 3 lagi
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 1
- Emory University Hospital/Winship Cancer Institute, Atlanta
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Mengambil pesertaFasa awal 1
- Emory University/Winship Cancer Institute, Atlanta
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Mengambil pesertaFasa 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Mengambil pesertaKajian pemerhatian
- Northside Hospital, Atlanta
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Mengambil pesertaFasa 1
- Emory University Hospital Midtown, Atlanta
- Emory University, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Atlanta
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- New York City, NY60 kajian
- Los Angeles, CA45 kajian
- Washington, DC41 kajian
- Arlington, VA41 kajian
- Chicago, IL41 kajian
- Nashville, TN40 kajian
- Baltimore, MD40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
Kajian lain di Atlanta
- Kanser (semua jenis)49 kajian
- Kanser Paru-paru Bukan Sel Kecil47 kajian
- Kanser Payudara41 kajian
- Mieloma Pelbagai41 kajian
- Kanser Prostat33 kajian
- Leukemia Mieloid Akut30 kajian
- Kanser Ovari29 kajian
- Kanser Kolorektal29 kajian
- Kanser Metastatik28 kajian
- Kegagalan Jantung25 kajian
- Gangguan Depresi Major25 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher24 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.